TG Therapeutics Inc (TGTX)

Fixed asset turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 329,004 262,359 340,582 280,254 222,343 180,883 18,875 6,331 2,784 5,025 6,961 7,912 6,689 4,406 2,414 907 152 152 152 152
Property, plant and equipment US$ in thousands — — — 66 95 133 206 237 307 376 447 526 600 600 597 488 481 378 331 320
Fixed asset turnover — — — 4,246.27 2,340.45 1,360.02 91.63 26.71 9.07 13.36 15.57 15.04 11.15 7.34 4.04 1.86 0.32 0.40 0.46 0.48

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $329,004K ÷ $—K
= —

The fixed asset turnover ratio for TG Therapeutics Inc has shown a fluctuating trend over the periods provided. The ratio measures how efficiently the company is generating revenue from its fixed assets.

From March 31, 2020, to December 31, 2021, the fixed asset turnover ratio was relatively low, ranging from 0.32 to 11.15. This indicates that the company was not efficiently utilizing its fixed assets to generate revenue during this period.

However, there was a significant uptick in the ratio from March 31, 2022, to September 30, 2023, where the ratio increased substantially from 15.04 to 1,360.02. This sharp increase suggests that the company improved its efficiency in utilizing fixed assets to generate revenue during this period.

By December 31, 2023, the fixed asset turnover ratio reached its peak at 2,340.45, indicating a remarkable improvement in asset utilization efficiency.

The ratio experienced a sharp decline by March 31, 2024, to 4,246.27, indicating a significant increase in revenue generated per fixed asset. This sudden increase could be due to various factors like asset disposals or changes in business operations.

The absence of data for the subsequent periods of June 30, 2024, and September 30, 2024, makes it difficult to assess the current trend in fixed asset turnover. It would be important to monitor future data to understand the continued efficiency of TG Therapeutics Inc in generating revenue from its fixed assets.